X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Price:
65
CNY
0.02%
Market Closed
Market Cap:
¥26.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
CN |
|
Carnival Industrial Corp
TWSE:1417
|
TW |
|
Jiangsu Jingxue Insulation Technology Co Ltd
SZSE:301010
|
CN |
|
eBASE Co Ltd
TSE:3835
|
JP |
|
S
|
Signatureglobal (India) Ltd
NSE:SIGNATURE
|
IN |
Income Statement
Earnings Waterfall
Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co Ltd
Income Statement
Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co Ltd
Currency: CNY
| Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||
| Interest Expense |
4
|
4
|
3
|
3
|
3
|
3
|
2
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Revenue |
597
N/A
|
665
+12%
|
730
+10%
|
771
+6%
|
771
0%
|
762
-1%
|
794
+4%
|
822
+4%
|
904
+10%
|
1 043
+15%
|
1 132
+9%
|
1 262
+11%
|
1 378
+9%
|
1 466
+6%
|
1 527
+4%
|
1 601
+5%
|
1 716
+7%
|
1 843
+7%
|
2 100
+14%
|
2 226
+6%
|
2 387
+7%
|
2 595
+9%
|
2 817
+9%
|
2 945
+5%
|
3 138
+7%
|
3 342
+7%
|
3 696
+11%
|
|
| Gross Profit | ||||||||||||||||||||||||||||
| Cost of Revenue |
(75)
|
(77)
|
(80)
|
(87)
|
(85)
|
(87)
|
(84)
|
(87)
|
(92)
|
(103)
|
(125)
|
(145)
|
(161)
|
(176)
|
(169)
|
(179)
|
(167)
|
(151)
|
(140)
|
(152)
|
(168)
|
(189)
|
(184)
|
(206)
|
(226)
|
(255)
|
(260)
|
|
| Gross Profit |
522
N/A
|
589
+13%
|
650
+10%
|
684
+5%
|
686
+0%
|
675
-2%
|
710
+5%
|
734
+3%
|
811
+10%
|
941
+16%
|
1 007
+7%
|
1 116
+11%
|
1 217
+9%
|
1 289
+6%
|
1 358
+5%
|
1 422
+5%
|
1 548
+9%
|
1 692
+9%
|
1 960
+16%
|
2 074
+6%
|
2 219
+7%
|
2 406
+8%
|
2 634
+9%
|
2 739
+4%
|
2 912
+6%
|
3 087
+6%
|
3 436
+11%
|
|
| Operating Income | ||||||||||||||||||||||||||||
| Operating Expenses |
(439)
|
(486)
|
(531)
|
(539)
|
(532)
|
(527)
|
(556)
|
(568)
|
(620)
|
(704)
|
(767)
|
(838)
|
(881)
|
(929)
|
(959)
|
(994)
|
(1 084)
|
(1 124)
|
(1 276)
|
(1 352)
|
(1 433)
|
(1 544)
|
(1 670)
|
(1 727)
|
(1 838)
|
(2 016)
|
(2 196)
|
|
| Selling, General & Administrative |
(397)
|
(442)
|
(486)
|
(506)
|
(495)
|
(494)
|
(504)
|
(505)
|
(552)
|
(628)
|
(701)
|
(772)
|
(833)
|
(852)
|
(843)
|
(867)
|
(921)
|
(952)
|
(1 064)
|
(1 127)
|
(1 182)
|
(1 273)
|
(1 401)
|
(1 445)
|
(1 514)
|
(1 673)
|
(1 812)
|
|
| Research & Development |
(49)
|
(49)
|
(49)
|
(53)
|
(58)
|
(59)
|
(73)
|
(79)
|
(82)
|
(89)
|
(78)
|
(85)
|
(95)
|
(126)
|
(146)
|
(167)
|
(175)
|
(192)
|
(226)
|
(236)
|
(267)
|
(280)
|
(288)
|
(318)
|
(356)
|
(381)
|
(363)
|
|
| Depreciation & Amortization |
0
|
(3)
|
(6)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(9)
|
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
(15)
|
0
|
0
|
0
|
(49)
|
|
| Other Operating Expenses |
7
|
8
|
10
|
19
|
21
|
28
|
27
|
17
|
13
|
13
|
19
|
19
|
46
|
49
|
39
|
40
|
12
|
20
|
25
|
11
|
16
|
9
|
33
|
35
|
32
|
39
|
27
|
|
| Operating Income |
83
N/A
|
102
+23%
|
119
+16%
|
145
+21%
|
154
+7%
|
149
-4%
|
154
+4%
|
167
+9%
|
192
+15%
|
237
+24%
|
240
+1%
|
278
+16%
|
336
+21%
|
360
+7%
|
398
+11%
|
428
+7%
|
464
+8%
|
569
+22%
|
685
+20%
|
722
+5%
|
786
+9%
|
862
+10%
|
963
+12%
|
1 012
+5%
|
1 074
+6%
|
1 071
0%
|
1 239
+16%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||
| Interest Income Expense |
(5)
|
(5)
|
(3)
|
(2)
|
(1)
|
1
|
4
|
6
|
8
|
9
|
8
|
9
|
8
|
9
|
8
|
9
|
7
|
7
|
9
|
10
|
11
|
11
|
7
|
8
|
8
|
8
|
12
|
|
| Non-Reccuring Items |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(13)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
|
| Total Other Income |
(23)
|
(25)
|
(25)
|
(26)
|
(26)
|
(24)
|
(18)
|
(20)
|
(25)
|
(31)
|
(31)
|
(41)
|
(45)
|
(52)
|
(51)
|
(50)
|
(44)
|
(39)
|
(39)
|
(38)
|
(38)
|
(34)
|
(40)
|
(37)
|
(41)
|
(63)
|
(75)
|
|
| Pre-Tax Income |
56
N/A
|
73
+31%
|
91
+25%
|
116
+28%
|
127
+9%
|
126
-1%
|
139
+11%
|
153
+10%
|
175
+14%
|
214
+23%
|
215
+0%
|
246
+14%
|
299
+22%
|
317
+6%
|
356
+12%
|
387
+9%
|
428
+10%
|
537
+25%
|
641
+19%
|
694
+8%
|
760
+9%
|
839
+10%
|
931
+11%
|
983
+6%
|
1 042
+6%
|
1 016
-2%
|
1 175
+16%
|
|
| Net Income | ||||||||||||||||||||||||||||
| Tax Provision |
(8)
|
(15)
|
(27)
|
(30)
|
(32)
|
(27)
|
(23)
|
(24)
|
(32)
|
(46)
|
(34)
|
(41)
|
(56)
|
(64)
|
(69)
|
(74)
|
(72)
|
(81)
|
(85)
|
(94)
|
(102)
|
(98)
|
(103)
|
(102)
|
(91)
|
(77)
|
(144)
|
|
| Income from Continuing Operations |
48
|
58
|
64
|
86
|
95
|
99
|
117
|
129
|
142
|
168
|
181
|
204
|
243
|
254
|
287
|
314
|
356
|
456
|
555
|
600
|
658
|
741
|
828
|
881
|
951
|
940
|
1 031
|
|
| Net Income (Common) |
48
N/A
|
58
+21%
|
64
+12%
|
86
+34%
|
95
+11%
|
99
+3%
|
117
+18%
|
129
+10%
|
142
+11%
|
168
+18%
|
181
+8%
|
204
+13%
|
243
+19%
|
254
+5%
|
287
+13%
|
314
+9%
|
356
+13%
|
456
+28%
|
555
+22%
|
600
+8%
|
658
+10%
|
741
+13%
|
828
+12%
|
881
+6%
|
951
+8%
|
940
-1%
|
1 031
+10%
|
|
| EPS (Diluted) |
0.13
N/A
|
0.15
+15%
|
0.18
+20%
|
0.23
+28%
|
0.25
+9%
|
0.25
N/A
|
0.29
+16%
|
0.31
+7%
|
0.34
+10%
|
0.4
+18%
|
0.45
+12%
|
0.5
+11%
|
0.6
+20%
|
0.63
+5%
|
0.71
+13%
|
0.77
+8%
|
0.87
+13%
|
1.12
+29%
|
1.37
+22%
|
1.48
+8%
|
1.62
+9%
|
1.82
+12%
|
2.03
+12%
|
2.17
+7%
|
2.34
+8%
|
2.31
-1%
|
2.52
+9%
|
|
Switch to:
Switch to:
See Also
Discover More
